Appendix 4E

• Revenue down 67% to $3.55m, excluding one-off Clinichain revenue, revenue increased 10%
• Net loss increased 95% to $13.23m due to revenue decline
• Cash and cash equivalents increased 405% to $2.43m

Cardiex Ltd reported revenue of $3,551,284 for the year ended 30 June 2025, down 67% from the prior year. However, $7,669,307 of the prior year revenue was recorded upon the early conclusion and subsequent payment in full of the multi-year Clinichain clinical trial. Excluding this one-off revenue, the company's revenue increased by 10% or $314,955. The Group's net loss for the period attributable to members increased by $6,460,270 or 95% to $13,225,635, largely due to the decrease in revenue. Total expenses in the year were $19,508,259, with the reduction in the second half of the year reflecting the streamlining initiatives put in place for both staff and product development costs. The company's balance sheet strengthened during the financial year, with increases in current assets and a reduction in current liabilities. Cash and cash equivalents increased by $1,951,668 or 405% to $2,433,097. The company issued 255,905,749 new shares during the year, including through placements, an entitlements offer, and the conversion of debt, strengthening its net asset position to $5,599,458.